Company Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.
It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD.
InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017.
The company was founded in 2007 and is headquartered in Jena, Germany.
| Country | Germany |
| Founded | 2007 |
| IPO Date | Nov 8, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Niels Riedemann |
Contact Details
Address: Winzerlaer Str. 2 Jena, 07745 Germany | |
| Phone | 49 3641 508 180 |
| Website | inflarx.de |
Stock Details
| Ticker Symbol | IFRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001708688 |
| CUSIP Number | N44821101 |
| ISIN Number | NL0012661870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prof. Niels C. Riedemann M.D., Ph.D. | Co-Founder, Chief Executive Officer and Executive Director |
| Prof. Renfeng Guo M.D. | Co-Founder, Chief Scientific Officer and Executive Director |
| Dr. Thomas Taapken Ph.D. | Chief Financial Officer |
| Derval O'Carroll | Senior Vice President and Global Head of Regulatory Affairs and Compliance |
| Dr. Camilla Chong M.D. | Chief Medical Officer |
| Jan Medina CFA | Head of Investor Relations and Vice President |
| Christian Schmid | Vice President and Head of Legal Affairs and General Counsel |
| Nicole Bertsch | Senior Director and Head of Human Resources |
| Dr. Maria Habel PH.D. | Vice President, Head of Preclinical Research & Development and QC |
| Kofi Boaten | Vice President and Head of Supply Quality and Clinical Trial Supplies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | 6-K | Report of foreign issuer |
| Mar 20, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Mar 16, 2026 | 6-K | Report of foreign issuer |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 8, 2026 | 6-K | Report of foreign issuer |
| Dec 30, 2025 | 6-K | Report of foreign issuer |
| Nov 10, 2025 | 6-K | Report of foreign issuer |
| Nov 10, 2025 | 6-K | Report of foreign issuer |
| Sep 12, 2025 | 6-K | Report of foreign issuer |